...other diagnostic companies. Kevin Noonan, a partner at McDonnell Boehnen Hulbert & Berghoff LLP, cited Sequenom Inc....
...for Section 101 damage. In the 2015 Ariosa Diagnostics Inc. v. Sequenom Inc. case before CAFC, Sequenom’s...
...as patent ineligible. The next year, Sequenom was acquired by Laboratory Corp. of America Holdings. Sequenom’s...

...or about $371 million including Sequenom’s net debt. The price is a 182% premium to Sequenom’s...
...June, the U.S. Supreme Court declined to review a lower court’s decision that had invalidated Sequenom’s...
...with nucleic acid analysis, as used in the company’s MaterniT21 Plus laboratory-developed test. In January, Sequenom...

...a 182% premium to Sequenom's close of $0.85 on Tuesday, before the deal was announced. Sequenom's...
...month, the U.S. Supreme Court declined to review a lower court's decision that had invalidated Sequenom's...
...nucleic acid analysis, as used in the company's MaterniT21 Plus laboratory-developed test. On June 27, Sequenom...

...6,258,540 covering prenatal diagnosis with nucleic acid analysis used in Sequenom’s MaterniT21 Plus laboratory-developed test. Sequenom...
...Prometheus Laboratories Inc. , which the appeals court used as rationale to invalidate Sequenom’s patent. Sequenom...
...had filed briefs supporting Sequenom. In an amicus brief submitted to SCOTUS in support of Sequenom...

...Court declined to review a lower court's decision that had invalidated a patent owned by Sequenom Inc....
...a prenatal diagnostic test. In that case, the CAFC upheld a lower court decision invalidating Sequenom's...

...Court declined to review a lower court's decision that had invalidated a patent owned by Sequenom Inc....
...Sequenom. In 2013, the U.S. District Court for the Northern District of California ruled that Sequenom's...
...Supreme Court's decision. In an amicus brief submitted to the Supreme Court in support of Sequenom...

...CEO and said chief commercial officer Matthew Posard departed. Welch was president and CEO of Sequenom Inc....

...Anthem Blue Cross and Blue Shield of Connecticut, Maine and New Hampshire will cover Sequenom’s noninvasive...
...company’s products include MaterniT21 Plus LDT, which detects trisomies along with fetal sex chromosomal aneuploidies. Sequenom Inc....

...12-mo op loss ended 12/31 1/7/16 Sequenom Inc. (NASDAQ:SQNM) 20% to 390 $76.2 9.65 12/31/15 $7.9 Sequenom...
...genomic laboratory in Research Triangle Park, N.C., and consolidate those operations in San Diego, Calif. Sequenom...

...San Diego. Sequenom will also look for commercialization partners for its cancer liquid biopsy assay. Sequenom...
...the company had $80.4 million in cash and a nine-month operating gain of $2.2 million. Sequenom Inc....